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PMW5
COST-EFFECTIVENESS ANALYSIS OF
CURRENTLY MARKETED LONG-TERM
CONTRACEPTIVES
Knight K, Reyes E,Wallace J, Chiou CF,Wade S, Borenstein J
Cedars-Sinai Health System, Zynx Health Incorporated,
Beverly Hills, CA, USA
OBJECTIVES: To compare the costs and beneﬁts, from
a health plan perspective, of contraceptive methods cur-
rently marketed in the United States among individuals
desiring long-term contraception.
METHODS: A semi-Markov model was constructed 
to compare cost-effectiveness among 14 contraceptive
strategies (including injectables, implants, oral contra-
ceptives, IUDs, barrier methods, and surgical methods).
Primary health states included method discontinuation,
initial/continued use, method failure and plan disenroll-
ment with transitions every year for ﬁve years. Costs for
method failure, other discontinuation, and method-
related events (amenorrhea, hysterectomy, menorrhagia,
urinary tract infection, and venous thromboembolism)
are included in the model. Baseline event rates, costs, and
method effects on rates were derived from a comprehen-
sive literature review, average wholesale drug prices, and
the 2000 Medicare Reimbursement Fee Schedule, in 
conjunction with expert opinion. One-way sensitivity
analyses were performed on several key variables.
RESULTS: The ﬁve most effective methods were vasec-
tomy, tubal ligation, implant, progestin-releasing IUD,
and copper IUD, with average effectiveness of (99.9%,
99.8%, 98.6%, 98.2% and 97.8%, respectively). The 
ﬁve least expensive methods were vasectomy, progestin-
releasing IUD, copper IUD, implant, and injectables 
with respective ﬁve-year costs/person of $800, $1,196,
$1,217, $1,237, and $1,764. Vasectomy dominated other
methods over ﬁve years. After excluding vasectomy, 
progestin-releasing IUD, implant and tubal ligation 
dominated, with a marginal cost-effectiveness of $71 per
additional percent of effectiveness between progestin-
releasing IUD and implant, and $958 between progestin-
releasing IUD and tubal ligation. The cost-effectiveness
ranking among methods did not vary signiﬁcantly in most
sensitivity analyses except those based on method costs.
CONCLUSIONS: Over ﬁve years, vasectomy is the most
cost-effective long-term contraceptive strategy. Among
long-term contraceptive options for women, progestin-
releasing IUD had a lower cost-effectiveness ratio than
either implant or tubal ligation and dominated all other
methods.
PMW6
COST EFFECTIVENESS MODELING COMPARING
RECOMBINANT FSH WITH URINARY FSH FOR
OVARIAN STIMULATION—A MULTINATIONAL
EVALUATION
Beresniak A1, Daya S2, Duru G3,Auray JP3
1Serono International SA, Geneva, Switzerland; 2McMaster
University, Hamilton, Ontario, Canada; 3Université Claude
Bernard Lyon,Villeurbanne, France
OBJECTIVES: The focus on cost-containment imposed
by shrinking national health care budgets is increasingly
putting pressure on investigators to demonstrate that
newer interventions are cost-effective. In assisted repro-
ductive technology (ART), a shift in usage is occurring
from urinary derived to biotechnology – derived (recom-
binant) gonadotropins for ovarian stimulation. Provision
of treatment with ART involves several cycles, each asso-
ciated with multiple steps with varying outcomes at each
step. To take into account all the situations that are pos-
sible during the repeated cycles of treatment when trying
to evaluate different ovarian stimulation regimens is a
complex task that requires large numbers of subjects to
adequately address the cost-effectiveness A more efﬁcient
approach is to employ modeling techniques that can
easily be applied to the different national health care
systems. The objective of this study was to compare the
cost-effectiveness of recombinant(r) FSH with urinary(u)
FSH in the UK, USA, Germany and Spain.
METHODS: The analyses used the Markov model and
Monte-Carlo simulations taking into account the differ-
ent health care environments in the four countries. For
each nation, costs were provided by their national for-
mulary and clinic tariff, and probabilities for outcomes
were obtained from randomized controlled trials, the
medical literature and national registries. The data were
they validated by a panel of national experts and the esti-
mation of variability in the transition probabilities was
also ratiﬁed by the panel. This approach provided a range
of transitional probabilities from which a precise stan-
dard deviation could be obtained for each outcome. The
ﬁnal Markov matrix included 300–600 health states 
that represented the complete ART process over multiple
cycles involving the transfer of fresh or cryopreserved
embryos.
RESULTS: Country Mean cost per pregnancy uFSH rFSH
Difference UK £6060 5906 154 USA $47,096 40,688
6408 Germany DM 45,510 43,311 2199 Spain PTAS
3,405,347 3,284,241 121,106
CONCLUSION: The studies conﬁrmed that rFSH is 
more cost-effective than uFSH for ovarian stimulation.
The lower average cost per pregnancy was observed con-
sistently in each country.
PMW7
IDENTIFYING PATIENT AND HOSPITAL-
RELATED PREDICTORS OF MATERNITY
LENGTH OF STAY AND TOTAL INPATIENT
CHARGES FOR OBSTETRICAL DELIVERIES IN A
NATIONAL SAMPLE
Mody R,Amonkar M, Kamat S
West Virginia University, Morgantown, WV, USA
Obstetrical delivery is the most frequent cause of 
hospital admissions (4 million) in the US.
OBJECTIVE: To assess the relationship of patient and
hospital-related characteristics with maternity length of
stay (LOS) and charges for obstetrical deliveries.
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METHODS: Records of 62,003 obstetrical deliveries
were extracted from a Nationwide Inpatient Sample of
the Healthcare Cost and Utilization Project data (DRG
371 for cesarean delivery without complications and 373
for vaginal delivery without complications). Regression
analyses were conducted to predict maternity LOS and
total charges based on type of delivery, age, race, number
of diagnoses at discharge, primary payer (Medicaid,
private insurance/HMO, self-pay, other), and hospital
characteristics of bed size, region (northeast, midwest,
south, west), location (rural, urban), teaching status, and
control/ownership.
RESULTS: In 1997, 82% of the deliveries were vaginal
while 18% were cesarean. Average LOS for vaginal and
cesarean deliveries was 1.86 and 3.36 days, respectively.
Mean total charges for vaginal deliveries were $3,778 as
compared to $7,243 for cesarean deliveries. Regression
results indicate that type of delivery was the strongest pre-
dictor of LOS and total charges. Women with a cesarean
delivery stayed on an average 1.3 days more in the 
hospital and incurred 64% more charges than women
with vaginal delivery. For vaginal delivery, an additional
day of hospitalization increased total charges by 12.4% 
as compared to 6.7% for cesarean delivery. Medicaid
patients had shorter LOS than private insurance/HMOs,
and longer LOS than self-paying patients. Northeast hos-
pitals had greater LOS while hospitals in the West had
higher charges. Urban hospitals and teaching hospitals
had higher LOS and charges.
CONCLUSIONS: Signiﬁcant variations in maternity LOS
and total charges were observed on the basis of type 
of delivery and hospital-related characteristics, which
warrant further investigation. Additionally, the impact of
LOS and total charges on mother and infant morbidity
should be explored.
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BENIGN PROSTATIC HYPERPLASIA:
RECOGNITION OF THE CONSEQUENCES OF
THE PATHOLOGY FOR THE SPOUSE
Taieb C, Cohen A, Myon E
PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France
Urinary problems secondary to benign prostatic hyper-
plasia (BPH) are found in 20 to 25% of the population
of men over 50 years of age. This is thus a public health
problem with a number of diagnostic, therapeutic and
economic facets. The severity of the problem is assessed
by the score obtained on the IPSS, a well known and
recognised questionnaire.
OBJECTIVE: As part of the growing importance attached
to the care giver, it is interesting to evaluate the conse-
quences of this masculine pathology for the spouse.
METHOD: As part of a cohort study (October
2000–March 2001), the GP gave the patient 2 «PFM»
(Patient Family Measurement) self-questionnaires for
himself and his spouse. For the analysis, 357 patient ques-
tionnaires and 316 spouse questionnaires were analysed.
The rate of return of the spouse questionnaires (88%) was
very satisfactory. The quality of life (QOL) of the patient
was measured by the SF12; the results consisted of 2
scores: mental (MCS-12) and physical (PCS-12).
RESULTS: The norm observed in the American popu-
lation, and from which the scores were standardised, 
was 50. In the patient where the QOL had deteriorated,
all the scores were lower than this norm, (PCS-12 = 46
& MCS-12 = 47.2). This deterioration in the quality of
life also applied to the spouse. (PCS-12 = 44.4 & 
MCS-12 = 45.9). For the PCS-12, the difference was 
signiﬁcant.
CONCLUSION: The rate of return of the spouse ques-
tionnaires showed the interest and involvement of spouses
in their husband’s pathology. The deterioration in the
quality of life of the spouse highlighted the impact of 
the disease on those around him. In both the patient 
and the spouse, the quality of life deteriorated with the
severity of the BPH.
PMW9
BENIGN PROSTATIC HYPERPLASIA:
CONSEQUENCES OF THE PATHOLOGY FOR
THE SPOUSE-RISK OF SOMNOLENCE
Taieb C1,Abbadie S2, Myon E1
1PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France; 2Economic Affairs, bioMérieux-
Pierre Fabre, Boulogne Billancourt, France
Urinary problems secondary to benign prostatic hyper-
plasia (BPH) are found in 20 to 25% of the population
of men over 50 years of age. This is thus a public health
problem with a number of diagnostic, therapeutic and
economic facets. Severity of the problem is assessed by
the score obtained on the IPSS, a well known and 
recognised questionnaire.
OBJECTIVE: As part of the growing importance attached
to the care giver, to evaluate the impact of this masculine
pathology upon the spouse.
METHOD: As part of a cohort study (10/2000–03/
2001), the GP gave the patient two «PFM» (Patient
Family Measurement) self-questionnaires for himself and
his spouse. During the consultation, 36.1% of the
patients spontaneously complained of sleep problems.
RESULTS: We are most interested in the impact of
daytime somnolence. The Epworth Scale was used to
evaluate this. The score observed in a control population
with normal sleeping habits is 5.9. For the analysis, we
analysed 482 patient questionnaires and 382 spouse ques-
tionnaires. The rate of return of the spouse questionnaires
(80%) was very satisfactory. For the patient, the risk of
daytime somnolence was made worse by the severity of
the urinary problem (slight—moderate—severe = 5.9–
6.4–8.9). For the spouses, the score rose to 5.2. For the
spouses, depending on the severity group slight—
moderate—severe of their husbands, the score rose to
